| 0 (0%) | 11-11 15:57 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 30.37 | 1-year : | 35.6 |
| Resists | First : | 26 | Second : | 30.47 |
| Pivot price | 23.7  |
|||
| Supports | First : | 18.76 | Second : | 15.6 |
| MAs | MA(5) : | 19.49 |
MA(20) : | 24.24 |
| MA(100) : | 23.27 |
MA(250) : | 24.46 |
|
| MACD | MACD : | -1.6 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 4.4 |
D(3) : | 4.2 |
| RSI | RSI(14): 34.8 |
|||
| 52-week | High : | 35.72 | Low : | 16.1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ APLS ] has closed above bottom band by 27.0%. Bollinger Bands are 209% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 19.62 - 19.81 | 19.81 - 19.92 |
| Low: | 18.55 - 18.8 | 18.8 - 18.94 |
| Close: | 18.72 - 19.12 | 19.12 - 19.36 |
Thu, 06 Nov 2025
APLS Stock: Wolfe Research Initiates Coverage with Peer Perform - GuruFocus
Wed, 05 Nov 2025
APLS: JP Morgan Lowers Price Target to $36, Maintains Overweight Rating | APLS Stock News - GuruFocus
Fri, 31 Oct 2025
Apellis Pharmaceuticals (APLS): Forecast 13% Annual Revenue Growth, Shares Trade at Deep Discount Heading Into Earnings - Yahoo Finance
Thu, 30 Oct 2025
Apellis Pharmaceuticals Inc (APLS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Thu, 30 Oct 2025
Apellis Pharmaceuticals (APLS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Thu, 23 Oct 2025
Apellis Pharmaceuticals, Inc. (APLS) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 126 (M) |
| Shares Float | 78 (M) |
| Held by Insiders | 13.6 (%) |
| Held by Institutions | 105.8 (%) |
| Shares Short | 18,060 (K) |
| Shares Short P.Month | 21,760 (K) |
| EPS | -1.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.24 |
| Profit Margin | -30.3 % |
| Operating Margin | -18.7 % |
| Return on Assets (ttm) | -13.8 % |
| Return on Equity (ttm) | -108.5 % |
| Qtrly Rev. Growth | -10.7 % |
| Gross Profit (p.s.) | 2.48 |
| Sales Per Share | 5.97 |
| EBITDA (p.s.) | -1.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 4 (M) |
| Levered Free Cash Flow | 106 (M) |
| PE Ratio | -10.7 |
| PEG Ratio | 0 |
| Price to Book value | 15.78 |
| Price to Sales | 3.27 |
| Price to Cash Flow | 550.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|